Research conducted at the Lady Davis Institute provides proof of concept that an existing drug holds promise for reversing loss of memory and brain lesions associated with Alzheimer disease.
New research conducted at the Lady Davis Institute (LDI) at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology (AD) in an animal model. Importantly, this drug has already proven to be non-toxic for humans in a clinical setting and could, therefore, be brought quickly to trials in humans against AD. These findings are published today in Nature Communications.
For years, Dr. Andréa LeBlanc, Senior Investigator at the LDI and Professor of Neurology and Neurosurgery at McGill University, has strived to identify early neurodegenerative events responsible for age-related memory loss. Her team discovered that the Caspase-6 enzyme is highly activated in Alzheimer disease brain lesions and associated with loss of memory. She, therefore, pursued the hypothesis that stopping Caspase-6 might provide relief from memory loss and stop progressive dementia. Since there are no specific Caspase-6 inhibitors, the LeBlanc team moved upstream, ultimately discovering that Caspase-1 was responsible for activating Caspase-6.
“This was a significant revelation because Caspase-1 inhibitors had been developed for treating inflammatory diseases,” explains Dr. LeBlanc. “Thus, we decided to test the effects of a particular Caspase-1 inhibitor, called VX-765, against memory loss and brain pathologies in a mouse model of Alzheimer disease.”
The work, first authored by Dr. Joseph Flores, a research associate in the LeBlanc lab, showed that VX-765 has an unprecedented beneficial effect in Alzheimer mice. The drug rapidly reverses memory loss, eliminates inflammation, and stops Alzheimer’s prototypical amyloid peptide accumulation in the mice brains. In addition to being safe for humans at relatively high doses for extended periods of time, it is capable of reaching the brain, a significant challenge in the development of drugs against disorders of the brain.
While Dr. LeBlanc cautions that there is a considerable bridge to cross between the mouse brain and that of a human, she believes that since her work has first identified the Caspase-1/Caspase-6 neurodegenerative pathway in human neurons and in human Alzheimer brains, there is a chance that this drug will work just as well in humans as it did in mice. Nevertheless, a clinical trial is needed to determine whether the drug will be beneficial against Alzheimer disease in humans.
Presently, there are no efficient treatments to significantly treat Alzheimer disease, the major affliction in a group of dementias that affect 47.5 million individuals worldwide.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Alzheimers Q&A: How can Amazon's Alexa or Google's Assistant help those with Alzheimer's or dementia?on March 22, 2020 at 1:00 pm
There are many innovations and assistive technologies available now that can ease caregiver responsibilities and promote greater independence and a quality of life for the person affected by Alzheimer ...
- Friday letters: Carbondale fire board, another use for PI, emergency tax fund, alzheimers, AQCCon March 22, 2020 at 1:50 am
Today I am writing in support of two outstanding candidates for the Carbondale & Rural Fire Protection District board of directors; Sydney Schalit and Gene Schilling. We need these two down to earth, ...
- Global Alzheimers Disease Drug Market Insights 2025 – Eisai, Pfizer, Novartis, Shire, Janssen, Forest Laboratories, H. Lundbeckon March 19, 2020 at 12:53 am
The global “Alzheimers Disease Drug Market” was valued at USD xx Million in 2020. The Alzheimers Disease Drug market research study providesits userswith the market size on the basis ofdifferent ...
- Alzheimers advocates convene in Annapolison March 18, 2020 at 10:01 pm
Please log in, or sign up for a new account and purchase a subscription to continue reading. Please log in, or sign up for a new account and purchase a subscription, or activate your access, to ...
- 'Broken Open' premieres to sold-out audience at Alzheimers Coachella Valley in Palm Deserton March 13, 2020 at 11:49 am
Broken Open' premieres to sold-out audience at Alzheimers Coachella Valley in Palm Desert In her very first play, Isabelle Sarfati brings us to the edge of the abyss and yet gives us a glimmer that ...
- Silver Alert issued for missing man with Alzheimers and dementiaon March 13, 2020 at 8:14 am
Wichita police have issued a Silver Alert for a 68-year-old man with Alzheimers and dementia. Police say Robert White was last seen around 7:30 a.m. Friday at his home in the 1300 block of West 1st ...
- Can I sign a directive to physicians for my mother who has Alzheimer’s?on March 11, 2020 at 10:21 am
Durable power of attorney does not give you the power to sign a directive to physicians for your mother, nor does the fact that you are also agent under her medical power of attorney.
- A Spring Fling supporting Alzheimers Fundraiseron March 10, 2020 at 9:18 pm
This fundraiser for the Alzheimer Society of B.C. will include funky, fun fashions, Hanna's Creative Cakes, coffee, tea, and a silent auction. Admission is $15.
- Don Trump Jr.: Biden exhibiting signs of Alzheimer's or dementia in 'snap back' at voteron March 10, 2020 at 11:12 am
Donald Trump Jr. said Joe Biden exhibited behavior associated with Alzheimer's disease or dementia after a blowup with a voter on the campaign trail.
via Bing News